Carcinoembryonic antigen-related cell adhesion molecules as surrogate markers for EGFR inhibitor sensitivity in human lung adenocarcinoma

British Journal of Cancer

Volumn 107, Issue 10, 2012, Pages 1745-1753

  Kobayashi, M ^a   Miki, Y ^a,b   Ebina, M ^a   Abe, K ^a,e   Mori, K ^c   Narumi, S ^a   Suzuki, T ^a   Sato, I ^d   Maemondo, M ^d   Endo, C ^a   Inoue, A ^a   Kumamoto, H ^b   Kondo, T ^a   Yamada Okabe, H ^c   Nukiwa, T ^a   Sasano, H ^a  

^a TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b TOHOKU UNIVERSITY   (Japan)

^c CHUGAI PHARMACEUTICAL CO LTD   (Japan)

^d Miyagi Cancer Center   (Japan)

^e SAITAMA MEDICAL UNIVERSITY   (Japan)

Author keywords

Carcinoembryonic antigen related cell adhesion molecule; EGFR inhibitor; Epidermal growth factor receptor (EGFR); Immunohistochemistry; Lung adenocarcinoma

Indexed keywords

CARCINOEMBRYONIC ANTIGEN RELATED CELL ADHESION MOLECULE 19; CARCINOEMBRYONIC ANTIGEN RELATED CELL ADHESION MOLECULE 3; CARCINOEMBRYONIC ANTIGEN RELATED CELL ADHESION MOLECULE 5; CARCINOEMBRYONIC ANTIGEN RELATED CELL ADHESION MOLECULE 6; CARCINOEMBRYONIC ANTIGEN RELATED CELL ADHESION MOLECULE 7; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; GEFITINIB; TUMOR MARKER; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CELL PROLIFERATION; DRUG EFFECT; FEMALE; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; LUNG ADENOCARCINOMA; MALE; MICROARRAY ANALYSIS; PRIORITY JOURNAL;

ADENOCARCINOMA; CARCINOEMBRYONIC ANTIGEN; CELL ADHESION; CELL ADHESION MOLECULES; CELL LINE, TUMOR; CELL PROLIFERATION; HUMANS; LUNG NEOPLASMS; MUTATION; PROTEIN KINASE INHIBITORS; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; TUMOR MARKERS, BIOLOGICAL;

EID: 84869096996     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2012.422     Document Type: Article

References (38)

1. Abdel-Aziz MM, Lotfy M, El-Kady IM, Abozaid M (2009) Mutant p53. protein in the serum of patients with colorectal cancer: correlation with the level of carcinoembryonic antigen and serum epidermal growth factor receptor. Cancer Detect Prev 32: 329-335.
2. Abou-Rjaily GA, Lee SJ, May D, Al-Share QY, Deangelis AM, Ruch RJ, Neumaier M, Kalthoff H, Lin SH, Najjar SM (2004) CEACAM1 modulates epidermal growth factor receptor-mediated cell proliferation. J Clin Invest 114: 944-952. (Pubitemid 39578722)
3. Asahina H, Yamazaki K, Kinoshita I, Sukoh N, Harada M, Yokouchi H, Ishida T, Ogura S, Kojima T, Okamoto Y, Fujita Y, Dosaka-Akita H, Isobe H, Nishimura M (2006) A phase II trial of gefitinib as firstline therapy for advanced non-small cell lung cancer with epidermal growth factor receptor mutations. Br J Cancer 95: 998-1004. (Pubitemid 44606825)
4. Bell DW, Gore I, Okimoto RA, Godin-Heymann N, Sordella R, Mulloy R, Sharma SV, Brannigan BW, Mohapatra G, Settleman J, Haber DA (2005) Inherited susceptibility to lung cancer may be associated with the T790M drug resistance mutation in EGFR. Nat Genet 37: 1315-1316. (Pubitemid 41722184)
5. Chen T, Gotschlich EC (1996) CGM1a antigen of neutrophils, a receptor of gonococcal opacity proteins. Proc Natl Acad Sci USA. 93: 14851-14856. (Pubitemid 26419058)
6. Cho BC, Im CK, Park MS, Kim SK, Chang J, Park JP, Choi HJ, Kim YJ, Shin SJ, Sohn JH, Kim H, Kim JH (2007) Phase II study of erlotinib in advanced non-small-cell lung cancer after failure of gefitinib. J Clin Oncol 25: 2528-2533. (Pubitemid 47041225)
7. Choi K, Creighton CJ, Stivers D, Fujimoto N, Kurie JM (2007) Transcriptional profiling of non-small cell lung cancer cells with activating EGFR somatic mutations. PLoS One 2: e1226.
8. Dango S, Sienel W, Schreiber M, Stremmel C, Kirschbaum A, Pantel K, Passlick B (2008) Elevated expression of carcinoembryonic antigenrelated cell adhesion molecule 1 (CEACAM-1) is associated with increased angiogenic potential in non-small-cell lung cancer. Lung Cancer 60: 426-433.
9. Gold P, Freedman SO (1965) Demonstration of tumor-specific antigens in human colonic carcinomata by immunological tolerance and absorption techniques. J Exp Med 121: 439-462.
10. Hansen HJ, Snyder JJ, Miller E, Vandevoorde JP, Miller ON, Hines LR, Burns JJ (1974) Carcinoembryonic antigen (CEA) assay. A laboratory adjunct in the diagnosis and management of cancer. Hum Pathol 5: 139-147.
11. Inoue A, Suzuki T, Fukuhara T, Maemondo M, Kimura Y, Morikawa N, Watanabe H, Saijo Y, Nukiwa T (2006) Prospective phase II study of gefitinib for chemotherapy-naive patients with advanced non-small-cell lung cancer with epidermal growth factor receptor gene mutations. J Clin Oncol 24: 3340-3346. (Pubitemid 46638887)
12. Isobe I, Michikawa M, Yanagisawa K (1999) Enhancement of MTT, a tetrazolium salt, exocytosis by amyroid b-protein and chloroquine in cultured rat astrocytes. Neurosci Lett 266: 129-132. (Pubitemid 29227341)
13. Kuespert K, Pils S, Hauck CR (2006) CEACAMs: Their role in physiology and pathophysiology. Curr Opin Cell Biol 18: 565-571. (Pubitemid 44332912)
14. Kuroki M, Matsuo Y, Kinugasa T, Matsuoka Y (1992) Three different NCA species, CGM6/CD67, NCA-95, and NCA-90, are comprised in the major 90 to 100-kDa band of granulocyte NCA detectable upon SDSpolyacrylamide gel electrophoresis. Biochem Biophys Res Commun 182: 501-506.
15. Lamerz R (1999) Role of tumour markers, cytogenetics. Ann Oncol 10: 145-149.
16. Lewis-Wambi JS, Cunliffe HE, Kim HR, Willis AL, Jordan VC (2008) Overexpression of CEACAM6 promotes migration and invasion of oestrogen-deprived breast cancer cells. Eur J Cancer 44: 1770-1779.
17. Li C, Iida M, Dunn EF, Ghia AJ, Wheeler DL (2009) Nuclear EGFR contributes to acquired resistance to cetuximab. Oncogene 28: 3801-3813.
18. Lin SY, Makino K, Xia W, Matin A, Wen Y, Kwong KY, Bourguignon L, Hung MC (2001) Nuclear localization of EGF receptor and its potential new role as a transcription factor. Nat Cell Biol 3: 802-808. (Pubitemid 32842685)
19. Lo HW, Hung MC (2006) Nuclear EGFR signalling network in cancers: linking EGFR pathway to cell cycle progression, nitric oxide pathway and patient survival. Br J Cancer 94: 184-188.
20. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, Harris PL, Haserlat SM, Supko JG, Haluska FG, Louis DN, Christiani DC, Settleman J, Haber DA (2004) Activating mutations in the epidermal growth factor receptor underlying responsiveness of nonYsmall-cell lung cancer to gefitinib. N Engl J Med 350: 2129-2139. (Pubitemid 38637993)
21. Maemondo M, Inoue A, Kobayashi K, Sugawara S, Oizumi S, Isobe H, Gemma A, Harada M, Yoshizawa H, Kinoshita I, Fujita Y, Okinaga S, Hirano H, Yoshimori K, Harada T, Ogura T, Ando M, Miyazawa H, Tanaka T, Saijo Y, Hagiwara K, Morita S, Nukiwa T, North-East Japan Study Group (2010) Gefitinib or chemotherapy for nonYsmall-cell lung cancer with mutated EGFR. N Engl J Med 362: 2380-2388.
22. Maraqa L, Cummings M, Peter MB, Shaaban AM, Horgan K, Hanby AM, Speirs V (2008) Carcinoembryonic antigen cell adhesion molecule 6. predicts breast cancer recurrence following adjuvant tamoxifen. Clin Cancer Res 14: 405-411. (Pubitemid 351226107)
23. Marti U, Burwen SJ, Wells A, Barker ME, Huling S, Feren AM, Jones AL (1991) Localization of epidermal growth factor receptor in hepatocyte nuclei. Hepatology 13: 15-20.
24. Messick CA, Sanchez J, Dejulius KL, Hammel J, Ishwaran H, Kalady MF (2010) CEACAM-7: A predictive marker for rectal cancer recurrence. Surgery 147: 713-719.
25. Niho S, Ichinose Y, Tamura T, Yamamoto N, Tsuboi M, Nakagawa K, Shinkai T, Jiang H, Nishiwaki Y, Fukuoka M (2007) Results of a randomized phase III study to compare the overall survival of gefitinib versus docetaxel in Japanese patients with non-small cell lung cancer who failed one or two chemotherapy regimens. J Clin Oncol 25: LBA7509 (2007 ASCO Annual Meeting Proceedings)\
26. Okamoto T, Nakamura T, Ikeda J, Maruyama R, Shoji F, Miyake T, Wataya H, Ichinose Y (2005) The serum CEA level can be a predictive factor for the efficacy of gefitinib in NSCLC patients. Eur J Cancer 41: 1286-1290.
27. Paez JG, Jänne PA, Lee JC, Tracy S, Greulich H, Gabriel S, Herman P, Kaye FJ, Lindeman N, Boggon TJ, Naoki K, Sasaki H, Fujii Y, Eck MJ, Sellers WR, Johnson BE, Meyerson M (2004) EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304: 1497-1500. (Pubitemid 38720929)
28. Shigematsu H, Lin L, Takahashi T, Nomura M, Suzuki M, Wistuba II, Fong KM, Lee H, Toyooka S, Shimizu N, Fujisawa T, Feng Z, Roth JA, Herz J, Minna JD, Gazdar AF (2005) Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J Natl Cancer Inst 97: 326-328.
29. Shoji F, Yoshino I, Yano T, Kometani T, Ohba T, Kouso H, Takenaka T, Miura N, Okazaki H, Maehara Y (2007) Serum carcinoembryonic antigen level is associated with epidermal growth factor receptor mutations in recurrent lung adenocarcinomas. Cancer 110: 2793-2798. (Pubitemid 350250351)
30. Sienel W, Dango S, Woelfle U, Morresi-Hauf A, Wagener C, Brümmer J, Mutschler W, Passlick B, Pantel K (2003) Elevated expression of carcinoembryonic antigen-related cell adhesion molecule 1 promotes progression of non-small cell lung cancer. Clin Cancer Res 9: 2260-2266. (Pubitemid 36687651)
31. Singer BB, Scheffrahn I, Kammerer R, Suttorp N, Ergun S, Slevogt H (2010) Deregulation of the CEACAM expression pattern causes undifferentiated cell growth in human lung adenocarcinoma cells. PLoS One 5: e8747.
32. Skubitz KM, Skubitz AP (2008) Interdependency of CEACAM-1, -3, -6, and -8 induced human neutrophil adhesion to endothelial cells. J Transl Med 6: 78.
33. Takano T, Fukui T, Ohe Y, Tsuta K, Yamamoto S, Nokihara H, Yamamoto N, Sekine I, Kunitoh H, Furuta K, Tamura T (2008) EGFR mutations predict survival benefit from gefitinib in patients with advanced lung adenocarcinoma: A historical comparison of patients treated before and after gefitinib approval in Japan. J Clin Oncol 26: 5589-5595.
34. Thatcher N, Chang A, Parikh P, Rodrigues Pereira J, Ciuleanu T, von Pawel J, Thongprasert S, Tan EH, Pemberton K, Archer V, Carroll K (2005) Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer (Iressa Survival Evaluation in Lung Cancer; ISEL). Lancet 366: 1527-1537. (Pubitemid 41540110)
35. Thomson S, Buck E, Petti F, Griffin G, Brown E, Ramnarine N, Iwata KK, Gibson N, Haley JD (2005) Epithelial to mesenchymal transition is a determinant of sensitivity of non-small-cell lung carcinoma cell lines and xenografts to epidermal growth factor receptor inhibition. Cancer Res 65: 9455-9462. (Pubitemid 41508014)
36. Mok TS, Wu YL, Thongprasert S, Yang CH, Chu DT, Saijo N, Sunpaweravong P, Han B, Margono B, Ichinose Y, Nishiwaki Y, Ohe Y, Yang JJ, Chewaskulyong B, Jiang H, Duffield EL, Watkins CL, Armour AA, Fukuoka M (2009) Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 361: 947-957.
37. Witta SE, Gemmill RM, Hirsch FR, Coldren CD, Hedman K, Ravdel L, Helfrich B, Dziadziuszko R, Chan DC, Sugita M, Chan Z, Baron A, Franklin W, Drabkin HA, Girard L, Gazdar AF, Minna JD, Bunn Jr PA (2006) Restoring E-cadherin expression increases sensitivity to epidermal growth factor receptor inhibitors in lung cancer cell lines. Cancer Res 66: 944-950. (Pubitemid 43165962)
38. Yauch RL, Januario T, Eberhard DA, Cavet G, Zhu W, Fu L, Pham TQ, Soriano R, Stinson J, Seshagiri S, Modrusan Z, Lin CY, O'Neill V, Amler LC (2005) Epithelial versus mesenchymal phenotype determines in vitro sensitivity and predicts clinical activity of erlotinib in lung cancer patients. Clin Cancer Res 11: 8686-8698(Pubitemid 43005918)